Recruiting

Neurobiological and Genomic Predictors of Relapse in Depression

The goal of this observational study is to test whether the discontinuation of antidepressant medications for patients with depression can be decided after the normalization of biological parameters. The main questions it aims are: 1. When patients with depression treated with antidepressants, does their brain activity also become normal? If so, 2. Then, can we stop the antidepressant treatment and expect minimum repeat of depression? The participants who receive a specific antidepressant treatment will be asked…

I'm interested View official listing
ClinicalTrials.gov IDNCT07328373
PhaseNot Applicable
Enrollment204
SponsorMehmet Kemal Arikan
Age18 Years – 65 Years
SexALL
I'm interested View official listing

Conditions studied

Healthy, Major Depressive Disorder (MDD)

About this study

The goal of this observational study is to test whether the discontinuation of antidepressant medications for patients with depression can be decided after the normalization of biological parameters. The main questions it aims are: 1. When patients with depression treated with antidepressants, does their brain activity also become normal? If so, 2. Then, can we stop the antidepressant treatment and expect minimum repeat of depression? The participants who receive a specific antidepressant treatment will be asked to: * Undergo quantitative electroencephalography (qEEG), * Record Event-related potential (ERP), * Record Sleep EEG * Answer Hamilton Depression Rating Scale question their psychiatrists asked * Give blood sample for genetic analysis * Repeat the above mentioned procedures for at least 3 times during their treatment period. Researchers will compare the results of patients with the results of healthy controls.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Outpatients * For patients, satisfying Major Depressive Disorder for Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) * Drug-free for at least 1-week Exclusion Criteria: * Any neurological and psychiatric comorbid conditions * Hearing loss * Physical diseases

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-05.